Vanda Pharmaceuticals Inc. Forecast, price target & analysts
Vanda Pharmaceuticals Inc. Target price 2025 - Analyst rating & recommendation
Vanda Pharmaceuticals Inc. Classifications & Recommendation:
Vanda Pharmaceuticals Inc. Price Target
| Target Price | $13.26 |
| Price | $4.41 |
| Potential |
200.68%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Vanda Pharmaceuticals Inc. 2026 .
The average Vanda Pharmaceuticals Inc. target price is $13.26.
This is
200.68%
register free of charge
$21.00
376.19%
register free of charge
$5.05
14.51%
register free of charge
|
|
| A rating was issued by 9 analysts: 7 Analysts recommend Vanda Pharmaceuticals Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Vanda Pharmaceuticals Inc. stock has an average upside potential 2026 of
200.68%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 198.77 | 227.23 |
| 3.18% | 14.32% | |
| EBITDA Margin | -16.80% | -16.74% |
| 172.85% | 0.35% | |
| Net Margin | -9.51% | -47.58% |
| 829.77% | 400.40% |
5 Analysts have issued a sales forecast Vanda Pharmaceuticals Inc. 2025 . The average Vanda Pharmaceuticals Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Vanda Pharmaceuticals Inc. EBITDA forecast 2025. The average Vanda Pharmaceuticals Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Vanda Pharmaceuticals Inc. Analysts have issued a net profit forecast 2025. The average Vanda Pharmaceuticals Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.33 | -1.83 |
| 925.00% | 454.55% | |
| P/E | negative | |
| EV/Sales | negative |
5 Analysts have issued a Vanda Pharmaceuticals Inc. forecast for earnings per share. The average Vanda Pharmaceuticals Inc. EPS is
This results in the following potential growth metrics and future valuations:
Vanda Pharmaceuticals Inc....
Current Vanda Pharmaceuticals Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Nov 05 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Oct 30 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 21 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 01 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 18 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 04 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Nov 05 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Oct 30 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 21 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 01 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 18 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 04 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
